Hallmarks of pancreatic cancer: spotlight on TAM receptors

Simple item page
dc.contributor.authorVázquez-Bellón, Núria
dc.contributor.authorMartínez Bosch, Neus
dc.contributor.authorGarcía de Frutos, Pablo
dc.contributor.authorNavarro Medrano, Pilar
dc.date.accessioned2025-04-24T06:11:55Z
dc.date.available2025-04-24T06:11:55Z
dc.date.issued2024
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need.
dc.description.sponsorshipThis work was supported by grants from the Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) (PI20/00625 and PI23/00591) to PN, 8th “Beca Carmen Delgado” to PN and PGF and grants from the MICIU (PID2021-123564OB-100) to PGF. The funders did not have any role in paper design, data collection, data analysis, interpretation, or writing of the paper. NV-B is supported by a FPU (“Formación de Profesorado Universitario”) predoctoral contract from the MICIU (FPU21/0928). The authors did not receive remuneration for their participation. We thank TPM Science for English proofreading and manuscript editing.
dc.format.mimetypeapplication/pdf
dc.identifier.citationVázquez-Bellón N, Martínez-Bosch N, García de Frutos P, Navarro P. Hallmarks of pancreatic cancer: spotlight on TAM receptors. EBioMedicine. 2024 Sep;107:105278. DOI: 10.1016/j.ebiom.2024.105278
dc.identifier.doihttp://dx.doi.org/10.1016/j.ebiom.2024.105278
dc.identifier.issn2352-3964
dc.identifier.urihttp://hdl.handle.net/10230/70184
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofEBioMedicine. 2024 Sep;107:105278
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/3PE/PID2021-123564OB-100
dc.rights© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.keywordDiagnosis
dc.subject.keywordPDAC
dc.subject.keywordPancreatic cancer
dc.subject.keywordTAM receptors
dc.subject.keywordTreatment
dc.titleHallmarks of pancreatic cancer: spotlight on TAM receptors
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Vazquez_ebm_hall.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
Download

Collections

License

Rights